References
- Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS – 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995;8:515–48.
- Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryotococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. HIV/AIDS CID 2001;33:691–9.
- Vidal JE, Penalva de Oliveira AC, Dauar RF. Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis 2013;17:353–62.
- Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Cryptococcal meningitis in non-HIV-infected patients. Q J Med 2000;93:245–51.
- Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Harrison TS, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291–322.
- World Health Organization. Rapid advice: diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children. WHO Document Production Services; 2011 pp 1–37.
- Lentnek A, Sande MA, Whetley RJ, McCracken GH, Scheld WM. Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. Clin Infect Dis 1992;15(Suppl 1):S189–94.
- Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013;368:1291–302.
- Loyse A, Wilson D, Meintjes G, Jarvis JN, Bicanc T, Bishop L, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012;54:121–8.
- Bandettini R, Castagnola E, Calvillo M, Micalizzi C, Raveqnani M, Pescetto L, et al. Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant. J Chemother 2009; 21:108–9.
- Nierenberg NE, Thompson GR, Lewis JS, Hogan BK, Patterson TF. Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol 2010;48:532–6.
- Sabbatani S, Manfredi R, Pavoni M, Consales A, Chiodo F. Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure. Mycopathologia 2004;158:165–71.
- Elenkov I. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int 2008;52:40–51.
- Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. HIV/AIDS CID 2003;36:789–94.
- Lee Y-C, Wang J-T, Sun H-Y, Chen Y-C. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol 2011;44:338–45.
- Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006;43:1069–73.
- Brew BJ. Cryptococcal meningitis. In: HIV neurology. Oxford University Press; 2001 pp 91–6.
- Kirkpatrick WR, Najvar LK, Bocanegra R, Patterson TF, Graybill JR. New guinea pig model of cryptococcal meningitis. Antimicrob Agents Chemother 2007;51: 3011–13.
- Mavrogiorgos N, Zaragoza O, Casadevall A, Nosanchuk JD. Efficacy of voriconazole in experimental Cryptococcus neoformans infection. Mycopathologia 2006;162:111–14.
- Zhong Y-H, Tan F, Li M, Liu J, Wang X, Yuan Y, et al. Comparisons of presentations and outcomes of cryptococcal meningitis between patients with and without hepatitis B virus infection. Int J Infect Dis 2014;20:31–6.